A running summary of major regulatory developments affecting the peptide industry, including compounding rules, safety alerts, and anti-doping updates.
Filed under regulation, written for regulator-compliance, pharmacist-compounder, clinician, founder-operator, evidence level regulatory-update.
Not medically reviewed. Last updated 2026-05-07. Nothing here is medical advice.
This resource tracks significant regulatory developments across major agencies that affect the peptide industry.
The FDA has scheduled a Pharmacy Compounding Advisory Committee meeting for July 23–24, 2026, to discuss several peptide-related bulk substances being considered for inclusion on the 503A Bulks List.
Following the resolution of the semaglutide shortage, the FDA's position on compounded copies of commercially available GLP-1 medications continues to evolve.
The FDA regularly issues warning letters to companies marketing unauthorized peptide products. Recent letters have targeted companies selling products labeled as "research use only" with implied human-use marketing.
Health Canada has warned consumers about unauthorized injectable peptide drugs promoted online. The advisory covers products marketed for anti-aging, weight loss, bodybuilding, and wellness.
The EMA continues to review and approve peptide-based medicines through centralized and national procedures.
The 2026 WADA Prohibited List is now in force, maintaining peptide hormones, growth factors, and related substances as prohibited categories in sport.
This resource is updated periodically. Check official agency websites for the most current information.
More guides: All guides, Safety centre, Peptide library.